Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for ESS 30005

Result Summary for ESS 30005

Result Summary

Protocol ID:	ESS 30005
Clinical Study ID:	ESS30005
Official Title:	A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol)
Phase:	Phase 4
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus I
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	Ziagen,ZIAGENAVIR
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Rodriguez AE, Hill-Zabala CE, Sloan LA, et al. Quadruple nucleoside/tide regimen of Trizivir (TZV) + Tenofovir (TDF) is effective following early virologic failure on an initial regimen containing a thymidine analog + lamivudine in combination with a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) (ESS30005, ZIP). In: 3rd IAS Conferences on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, July 24-27, 2005, Poster No. WePE6.3c03. Rodriguez AE, Hill-Zabala CE, Sloan LA, et al. Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and lamivudine can be successfully treated with a quadruple-nucleoside regimen. J Acquir Immune Defic Syndr 2006; 41(1):127-129.